242 related articles for article (PubMed ID: 19879939)
1. Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson's disease.
Samoylenko V; Rahman MM; Tekwani BL; Tripathi LM; Wang YH; Khan SI; Khan IA; Miller LS; Joshi VC; Muhammad I
J Ethnopharmacol; 2010 Feb; 127(2):357-67. PubMed ID: 19879939
[TBL] [Abstract][Full Text] [Related]
2. Composition, standardization and chemical profiling of Banisteriopsis caapi, a plant for the treatment of neurodegenerative disorders relevant to Parkinson's disease.
Wang YH; Samoylenko V; Tekwani BL; Khan IA; Miller LS; Chaurasiya ND; Rahman MM; Tripathi LM; Khan SI; Joshi VC; Wigger FT; Muhammad I
J Ethnopharmacol; 2010 Apr; 128(3):662-71. PubMed ID: 20219660
[TBL] [Abstract][Full Text] [Related]
3. Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism.
Schwarz MJ; Houghton PJ; Rose S; Jenner P; Lees AD
Pharmacol Biochem Behav; 2003 Jun; 75(3):627-33. PubMed ID: 12895680
[TBL] [Abstract][Full Text] [Related]
4. Components of
Santos BWL; Moreira DC; Borges TKDS; Caldas ED
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458698
[No Abstract] [Full Text] [Related]
5. The effect of Banisteriopsis caapi (B. caapi) on the motor deficits in the MPTP-treated common marmoset model of Parkinson's disease.
Fisher R; Lincoln L; Jackson MJ; Abbate V; Jenner P; Hider R; Lees A; Rose S
Phytother Res; 2018 Apr; 32(4):678-687. PubMed ID: 29368409
[TBL] [Abstract][Full Text] [Related]
6. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca.
McKenna DJ; Towers GH; Abbott F
J Ethnopharmacol; 1984 Apr; 10(2):195-223. PubMed ID: 6587171
[TBL] [Abstract][Full Text] [Related]
7. Biodiversity of β-Carboline Profile of
Santos BWL; Oliveira RC; Sonsin-Oliveira J; Fagg CW; Barbosa JBF; Caldas ED
Plants (Basel); 2020 Jul; 9(7):. PubMed ID: 32660098
[TBL] [Abstract][Full Text] [Related]
8. beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO).
Herraiz T; González D; Ancín-Azpilicueta C; Arán VJ; Guillén H
Food Chem Toxicol; 2010 Mar; 48(3):839-45. PubMed ID: 20036304
[TBL] [Abstract][Full Text] [Related]
9. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
[TBL] [Abstract][Full Text] [Related]
10. Mutagenicity of Ayahuasca and Their Constituents to the Salmonella/Microsome Assay.
Kummrow F; Maselli BS; Lanaro R; Costa JL; Umbuzeiro GA; Linardi A
Environ Mol Mutagen; 2019 Apr; 60(3):269-276. PubMed ID: 30488498
[TBL] [Abstract][Full Text] [Related]
11. Monoamine Oxidase Inhibition by Plant-Derived β-Carbolines; Implications for the Psychopharmacology of Tobacco and Ayahuasca.
Berlowitz I; Egger K; Cumming P
Front Pharmacol; 2022; 13():886408. PubMed ID: 35600851
[TBL] [Abstract][Full Text] [Related]
12. Analysis of monoamine oxidase enzymatic activity by reversed-phase high performance liquid chromatography and inhibition by beta-carboline alkaloids occurring in foods and plants.
Herraiz T; Chaparro C
J Chromatogr A; 2006 Jul; 1120(1-2):237-43. PubMed ID: 16386263
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA
Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127
[TBL] [Abstract][Full Text] [Related]
14. The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro.
Morales-García JA; de la Fuente Revenga M; Alonso-Gil S; Rodríguez-Franco MI; Feilding A; Perez-Castillo A; Riba J
Sci Rep; 2017 Jul; 7(1):5309. PubMed ID: 28706205
[TBL] [Abstract][Full Text] [Related]
15. Phytochemical analyses of Banisteriopsis caapi and Psychotria viridis.
Callaway JC; Brito GS; Neves ES
J Psychoactive Drugs; 2005 Jun; 37(2):145-50. PubMed ID: 16149327
[TBL] [Abstract][Full Text] [Related]
16. Various alkaloid profiles in decoctions of Banisteriopsis caapi.
Callaway JC
J Psychoactive Drugs; 2005 Jun; 37(2):151-5. PubMed ID: 16149328
[TBL] [Abstract][Full Text] [Related]
17. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
18. Reassessing the cultural and psychopharmacological significance of Banisteriopsis caapi: preparation, classification and use among the Piaroa of Southern Venezuela.
Rodd R
J Psychoactive Drugs; 2008 Sep; 40(3):301-7. PubMed ID: 19004422
[TBL] [Abstract][Full Text] [Related]
19. Synthetic and Natural Monoamine Oxidase Inhibitors as Potential Lead Compounds for Effective Therapeutics.
Pathak A; Srivastava AK; Singour PK; Gouda P
Cent Nerv Syst Agents Med Chem; 2016; 16(2):81-97. PubMed ID: 26104056
[TBL] [Abstract][Full Text] [Related]
20. Development of methylthiosemicarbazones as new reversible monoamine oxidase-B inhibitors for the treatment of Parkinson's disease.
Mathew GE; Oh JM; Mohan K; Tengli A; Mathew B; Kim H
J Biomol Struct Dyn; 2021 Aug; 39(13):4786-4794. PubMed ID: 32588753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
